Home » Stocks » CRY

CryoLife, Inc. (CRY)

Stock Price: $25.24 USD -1.07 (-4.07%)
Updated Feb 25, 2021 4:00 PM EST - Market closed
Market Cap 1.02B
Revenue (ttm) 253.23M
Net Income (ttm) -16.68M
Shares Out 37.86M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE 357.14
Dividend $0.03
Dividend Yield 0.12%
Trading Day February 25
Last Price $25.24
Previous Close $26.31
Change ($) -1.07
Change (%) -4.07%
Day's Open 26.39
Day's Range 25.05 - 26.55
Day's Volume 172,935
52-Week Range 12.63 - 26.60

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 2 weeks ago

CryoLife (CRY) delivered earnings and revenue surprises of 1100.00% and 4.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 2 weeks ago

Shares of Cryolife (NYSE:CRY) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 81.82% over the past year to $0.20, which beat ...

Seeking Alpha - 2 months ago

CryoLife has a resilient portfolio mix that is bolstered by upcoming regulatory catalysts. The company has decent upside potential through operations, however, this may already be reflected in...

PRNewsWire - 3 months ago

ATLANTA, Nov. 19, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will host a webcast for inv...

Seeking Alpha - 3 months ago

CryoLife's (CRY) CEO Pat Mackin on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

CryoLife (CRY) delivered earnings and revenue surprises of 1400.00% and 12.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 4 months ago

ATLANTA, Oct. 21, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2020 third quarter financial r...

PRNewsWire - 5 months ago

ATLANTA, Sept. 8, 2020 /PRNewswire/ -- CryoLife, Inc.

PRNewsWire - 5 months ago

ATLANTA, Sept. 2, 2020 /PRNewswire/ -- CryoLife, Inc.

Seeking Alpha - 6 months ago

CryoLife's (CRY) CEO Pat Mackin on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

CryoLife (CRY) delivered earnings and revenue surprises of 33.33% and 4.82%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 6 months ago

ATLANTA, July 30, 2020 /PRNewswire/ -- Second Quarter and Recent Business Highlights: Achieved total revenues of $53.8 million in the second quarter 2020 versus $71.1 million in the second qua...

Zacks Investment Research - 7 months ago

CryoLife (CRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 7 months ago

ATLANTA, July 21, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2020 second quarter financial ...

PRNewsWire - 8 months ago

ATLANTA, June 19, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) ("CryoLife" or "the Company"), a leading cardiac and vascular surgery company focused on aortic disease, today announced the p...

Market Watch - 8 months ago

CryoLife Inc. CRY, -0.72% said Thursday it is planning to offer $100 million in convertible senior notes that mature in 2024 in a private placement, joining the many companies issuing debt to ...

PRNewsWire - 8 months ago

ATLANTA, June 18, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) ("CryoLife" or "the Company"), a leading cardiac and vascular surgery company focused on aortic disease, today announced that ...

Seeking Alpha - 9 months ago

CryoLife, Inc. (CRY) CEO Pat Mackin on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

CryoLife (CRY) delivered earnings and revenue surprises of -500.00% and 1.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 11 months ago

CryoLife's (CRY) On-X AAP completes the company's On-Xs heart valve portfolio.

Seeking Alpha - 1 year ago

CryoLife, Inc. (CRY) CEO Pat MacKin on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

CryoLife (CRY) delivered earnings and revenue surprises of 42.86% and -4.46%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

CryoLife (CRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Figuring out bloated toxic stocks on a regular basis and discarding them at the right time is the key to successful investing.

Other stocks mentioned: BAK, ETSY, FSV, TAST
Seeking Alpha - 1 year ago

CryoLife, Inc. (CRY) CEO Pat MacKin on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

CryoLife (CRY) delivered earnings and revenue surprises of 50.00% and -1.91%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

CryoLife (CRY) eyes to expand the portfolio of aortic care, with endovascular stent graft system.

Zacks Investment Research - 1 year ago

Overhyped toxic stocks are vulnerable to external shocks and burdened with huge amount of debt.

Other stocks mentioned: CALX, CVA, GTT
Seeking Alpha - 1 year ago

CryoLife's (CRY) CEO Pat Mackin on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

CryoLife (CRY) delivered earnings and revenue surprises of 37.50% and 0.20%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 1 year ago

CryoLife's (CRY) CEO Patrick Mackin on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

CryoLife (CRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About CRY

CryoLife manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS, a hybrid stent graft system. The company also provides E-xtra DESIGN... [Read more...]

Industry
Medical Devices
IPO Date
Feb 11, 1993
CEO
James Mackin
Employees
1,200
Stock Exchange
NYSE
Ticker Symbol
CRY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for CryoLife stock is "Strong Buy." The 12-month stock price forecast is 30.92, which is an increase of 22.50% from the latest price.

Price Target
$30.92
(22.50% upside)
Analyst Consensus: Strong Buy